(Stroke. 2000;31:193.)
© 2000 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, Washington University School of Medicine, and Department of Anatomy and Neurobiology, St Louis University (X.M.X.), St Louis, Mo.
Correspondence to Chung Y. Hsu, MD, PhD, Department of Neurology, Box 8111, Washington University School of Medicine, 660 S. Euclid Ave, St Louis, MO 63110. E-mail hsuc{at}neuro.wustl.edu
| Abstract |
|---|
|
|
|---|
MethodsLPS (0.05 mg/kg SC) or vehicle was given to Long-Evans male rats 24 hours before ischemia. Focal cerebral ischemia was induced by temporary ligation of the right middle cerebral artery and both common carotid arteries for 45 minutes. Animals were killed 6 and 24 hours after reperfusion to determine the extent of PMN infiltration (myeloperoxidase assay), brain edema (wet-dry weight method), and vascular injury (fluorescein isothiocyanateconjugated dextran extravasation). The infarct volumes were measured on the basis of TTC stain 24 hours after ischemia.
ResultsLPS had little effect on body temperature or peripheral white count but substantially enhanced PMN infiltration into the ischemic right middle cerebral artery cortex on the basis of myeloperoxidase activity (6 hours: control, 0 U/g; LPS, 0.186±0.025 U/g; 24 hours: control, 0.185±0.025 U/g; LPS, 0.290±0.040 U/g; P<0.001) and morphological studies. The extent of vascular injury defined by the extravasation of fluorescein isothiocyanateconjugated dextran into the ischemic tissue (6 hours: control, 3.11±0.41 µL/mg protein; LPS, 0.48±0.16 µL/mg protein; 24 hours: control, 1.77±0.23 µL/mg protein; LPS, 0.90±0.19 µL/mg protein; P<0.001) and brain edema determined by the brain water content (6 hours: control, 84.77±1.63%; LPS, 82.09±1.25%; 24 hours: control, 89.40±0.43%; LPS, 87.88±0.58%; P<0.01) were paradoxically reduced by LPS priming. LPS-primed rats also had smaller infarct volumes (control, 135±5 mm3; LPS, 108±12 mm3; P<0.05).
ConclusionsEnhanced postischemic PMN infiltration is anticipated to facilitate ischemic brain injury. Contrary to this expectation, results from the present study suggest that an increase in postischemic PMN infiltration after LPS priming was not detrimental. These findings challenge the notion that postischemic PMN infiltration is uniformly deleterious.
Key Words: blood vessels brain edema cerebral ischemia inflammation neutrophils
| Introduction |
|---|
|
|
|---|
Recent bacterial and viral infection, especially in the preceding week, has been implicated as a risk factor of ischemic stroke.23 Activated PMNs in infection stimulate the recruitment and aggregation of platelets by releasing cathepsin G, a potent platelet agonist,24 platelet activating factor, and leukotrienes.25 This may activate the coagulation cascade or induce a procoagulant state during and after infection, leading to the development of acute ischemic stroke.23 Lipopolysaccharide (LPS), an endotoxin released by gram-negative bacteria, enhances overall PMN reactivity.26 In view of the reported detrimental role of PMN infiltration in cerebral ischemia/reperfusion and prior infection as a precipitating factor for stroke, we sought to further characterize the role of PMNs in ischemic brain injury by using LPS to enhance postischemic PMN infiltration in a stroke model featuring focal cerebral ischemia/reperfusion.
| Materials and Methods |
|---|
|
|
|---|
Stroke Model
The method for inducing severe ischemia in the cerebral
cortex of the right middle cerebral artery (MCA) territory in rats has
been described in detail.27 28 In brief, Long-Evans male
rats were anesthetized with injection of chloral hydrate (400
mg/kg IP). The right MCA was exposed by microsurgical techniques. A
2-mm burr hole was made at the junction of the zygomatic arch and
squamous bone, allowing MCA ligation with the use of 10-0 suture. Both
common carotid arteries (CCAs) were then occluded with nontraumatic
aneurysm clips. In the present study, the duration of
3-vessel occlusion was 45 minutes. After ischemia, both the
ligature on the right MCA and aneurysm clips on CCAs were
removed. Before surgery, a blood sample was collected for
peripheral white count. During ischemia and for 30
minutes after ischemia, body and left temporalis muscle
temperatures were kept at 37±0.5°C with a heating lamp linked to
thermostatic devices (Versa-Therm 2156, Cole-Parmer) and
temperature probes, as described previously.27
Arterial blood gases (Blood Gas Analyzer, model
238, Ciba Corning), mean arterial pressure (Digi-Med Blood
Pressure Analyzer, Micro-Med, Inc), heart rate, and plasma
glucose (Precision Glucose Analyzer, Medisense Inc) were also
monitored before ischemia, during ischemia, and for 30
minutes after initiation of reperfusion.28 After
ischemia, all rats were kept in incubators ventilated at 24°C
until the conclusion of the experiment 24 hours later.
Treatment With LPS
Animals were divided into LPS-primed and control groups. In the
LPS group, rats were given a subcutaneous injection of LPS
(Salmonella abortus equi, Sigma) at a dose of 0.05 mg/kg 24
hours before ischemia was induced. Preliminary studies with
various doses of LPS showed that this dosing schedule did not cause
apparent sickness or substantial alteration of
physiological variables. The control group
received vehicle injection 24 hours before ischemia.
Measurement of Myeloperoxidase
Myeloperoxidase (MPO) activity has been used to determine
quantitatively the extent of PMN infiltration.29 30 Six
and 24 hours after ischemia, rats were perfused with 200 mL of
saline intracardiacally under anesthesia. The right MCA
cortex was dissected and stored at -70°C until assay for MPO. MPO
assay has been previously described.30 Briefly, the MCA
cortex was homogenized in 0.05 mol/L potassium phosphate
buffer (pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide.
The supernatant derived from centrifugation at
27 000g for 15 minutes was assayed for MPO activity. MPO
activity was measured spectrophotometrically in 2.9 mL of 0.05 mol/L
phosphate buffer (pH 6.0) containing 0.53 nmol/L dianisidine
dihydrochloride, 0.15 mmol/L
H2O2, and 0.1 mL of the
supernatant. One unit of MPO activity was defined as that degrading
1 µmol of H2O2 in 1
minute.
Histopathology
After perfusion with 200 mL of saline and 400 mL of 4%
paraformaldehyde in phosphate-buffered saline (pH 7.4),
the brain was placed in the same fixative overnight and was embedded in
paraffin. Coronal sections of the brain, 1 mm behind the bregma,
were cut at 6 µm and stained with hematoxylin and eosin. Infarct
areas in the LPS versus the control groups were searched for PMNs. The
mature form of these cells has a lobulated and variably shaped nucleus
and neutrophilic granular cytoplasm.
Determination of Extent of Vascular Injury
Increase in vascular permeability, a sensitive and specific
indicator of vascular injury, is one of the important elements of an
inflammatory response after an ischemic event.31
The increase in vascular permeability was measured on the basis of the
extent of extravasation of fluorescein
isothiocyanateconjugated dextran (FITC-D) (molecular weight,
71 200), as previously described.32 Briefly,
FITC-D (20 mg/kg) was administered by intravenous infusion
2 hours before the animals were killed by intracardiac perfusion with
200 mL of saline under anesthesia. The ischemic
right MCA cortex was then dissected and homogenized in 1.0
mL of 5% trichloroacetic acid and centrifuged at
27 000g for 20 minutes. A 0.8-mL aliquot of the supernatant
was mixed with 0.2 mol/L Tris buffer (pH 8.2) to measure the FITC-D
fluorescence intensity at 490 nm for excitation and 521 nm for
emission. A sample of blood was obtained from the heart before
perfusion. For the assay of FITC-D levels in plasma, 10 µL of plasma
was mixed with 1.0 mL of 5% trichloroacetic acid. After
centrifugation, 0.8 mL of the supernatant was added to
0.2 mol/L Tris buffer (pH 8.2), and FITC-D fluorescence was
determined with the use of the same procedure for the brain. The extent
of vascular injury was estimated by a vascular injury index
(VII),32 derived from the following
formula: FITC-D in Right MCA Cortex/Protein Content in
![]() | (1) |
Measurement of Brain Edema
Determination of the extent of brain edema by the wet-dry method
has been described previously.33 The ischemic MCA
cortex was removed in a humidity chamber, and the wet weight was
measured immediately. The ischemic cortex was dried at 100°C
to a constant weight for the determination of dry weight. Brain edema
was determined by calculating tissue water content according to the
following formula: Percentage of Brain Water Content=(1-Dry Weight/Wet
Weight)x100%.
Morphometric Analysis of Infarct Volume
Infarct areas were demarcated by
2,3,5-triphenyltetrazolium chloride (TTC)
(Sigma) staining, and infarct volumes were calculated by the
"indirect" morphometric analysis method.33 In
brief, animals were killed with an overdose of pentobarbital (100 mg/kg
IP), and brains were sliced into 2-mm coronal sections with the use of
a brain matrix (Harvard Bioscience). The brain sections were incubated
in phosphate-buffered saline containing 2% TTC at 37°C for 20
minutes and subsequently stored in 10% phosphate-buffered formalin.
The infarct area of each brain slice was determined with an image
analyzer (DUMAS, Drexel University). The volume of the infarct
was calculated by summing the infarct areas measured in the component
brain slices. TTC-defined infarct volumes correlated with those
measured by a conventional histological method with the
use of hematoxylin and eosin stain.33 The morphometric
analysis of infarct volume, in which the indirect method was
used to correct for biases caused by brain edema, was described in
detail elsewhere.33
Statistical Analysis
Data are expressed as mean±SD. Multiple samples were
analyzed by 1-way ANOVA followed by a post hoc Tukey test
corrected for multiple comparisons. Comparisons of changes in
variables over time were made with the use of 2-way ANOVA.
Differences between 2 groups (LPS primed versus control) were
analyzed by Students t test. A P value
<0.05 was considered significant.
| Results |
|---|
|
|
|---|
(TNF-
) or IL-1 were not increased with this dose of LPS
(data not shown). MPO activity in the brain was measured to assess the
extent of PMN infiltration in the ischemic cortex. The
sensitivity of MPO assay is 5±1x10-3
U/min.30 MPO activity was significantly higher at both 6
and 24 hours after ischemia in the LPS group than in the
control group (Figure 2
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The present study was undertaken to determine whether LPS priming
enhances postischemic PMN infiltration and consequently
accentuates acute ischemic brain injury, assuming a deleterious
role of PMNs in focal cerebral ischemia. LPS is a pluripotent
activator of PMNs. LPS stimulates PMNs in various ways,
including enhancement of PMN adherence to endothelial
cells.26 34 LPS also primes PMNs to release superoxide
(O2-) in response to other
stimuli.26 Its lipid A part activates the
complement C5a, which is a potent chemoattractant for PMNs. LPS priming
leads to increased production of the acute phase reactants
(IL-1 and TNF-
) and leukotriene
B4, which are also chemoattractants for
PMNs.34 LPS (0.05 mg/kg) given subcutaneously 24 hours
before ischemia was chosen from a series of preliminary studies
to avoid inflammatory reactions including fever, leukocytosis,
hypotension, and other serious systemic effects that may confound
ischemic outcomes. There was no substantial alteration of body
temperature or increase in peripheral white counts in the
LPS-primed rats compared with the controls. The plasma levels of
TNF-
or IL-1 were not elevated with this dose of LPS.
Arterial blood gases, heart rate, mean arterial
pressure, and plasma glucose were also not significantly altered in the
LPS group. These findings indicate that the dose of LPS (0.05 mg/kg)
used to prime PMNs did not itself cause a substantial inflammatory
reaction or cardiovascular dysfunction in rats that
were subjected to focal cerebral ischemia 24 hours later.
However, a single dose of LPS apparently primed PMNs for >24 hours,
leading to an enhanced infiltration into the ischemic cortex,
as reflected by the substantial increase in MPO activity. MPO assay is
a quantitative measure of the extent of PMN infiltration. Other
inflammatory cells in brain, such as monocytes and activated
microglia/macrophages, may also contain this enzyme, but to a
much lesser extent.35 Furthermore, the mononuclear cells
represent only a very small percentage of activated
cells at the inflammation site in the early stage of
postischemic inflammation reaction.8 36 Very
few monocytes or microglia/macrophage were noted on
morphological examination in the present study. However, a slight
contribution of these mononuclear cells to the MPO assay cannot
be completely ruled out.
Knowing the possible contributions of PMNs to the secondary injury processes after ischemia, we had expected that an increase in PMNs at the ischemic site would lead to greater acute brain injury. The fact that infection in the preceding week is a major risk factor for ischemic stroke also suggests that enhanced PMN activity may be detrimental in the setting of focal cerebral ischemia/reperfusion.23 Clinical studies have also suggested a positive correlation between activated PMNs and exacerbation of acute ischemic injury in stroke patients.22 37 Unexpectedly, we noted a significant reduction in vascular injury reflected by the extent of FITC-D extravasation. The brain water content and infarct volumes were also significantly reduced in the LPS group, in which the postischemic PMN infiltration in the ischemic cortex was greatly enhanced. These findings contradict a notion that an increase in PMN infiltration in the ischemic brain is invariably associated with a greater extent of tissue damage. It should be noted that the role of PMNs in acute ischemic brain injury has not been clearly delineated. Certain therapeutic strategies directed at reducing PMN infiltration or inhibiting PMN activation have failed in selected stroke models.38 39 A recently concluded double-blinded, randomized, placebo-controlled trial also showed that antiICAM-1 antibody was not effective and might even be detrimental in patients with acute ischemic stroke.40 Results from an animal study have also weakened the likelihood that infiltrating PMNs are invariably detrimental in ischemia/reperfusion injury.41
Preconditioning with LPS seemed to have an overall protective effect on
the ischemic brain. LPS priming that increased tolerance
against focal cerebral ischemic insult could be due to its
stimulation of TNF-
expression,42 since TNF-
has
also been shown to confer protection against focal cerebral
ischemia.43 44 However, LPS45 and
TNF-
46 47 could be deleterious, exacerbating
ischemic and hemorrhagic lesions in rats with inherent stroke
risk factors. These observations suggest that effects of LPS priming
may be variable depending on the physiological
states and the presence of certain risk factors for vascular injury.
Other possible mechanisms of LPS-induced tolerance against
ischemia could be due to increased production of nitric
oxide,48 upregulation of antioxidants,49 or
de novo synthesis of protective proteins independent of
TNF-
.50 LPS pretreatment does not seem to affect the
cerebral blood flow immediately after MCA occlusion but may diminish
the severity of secondary microvascular perfusion
deficits.51
In conclusion, the present study shows that an increase in
postischemic PMN infiltration under a selected experimental
paradigm did not accentuate acute ischemic brain injury. These
findings are compatible with the notion that PMN infiltration into the
ischemic brain may not be uniformly deleterious. Further
studies are needed to fully explore the complex roles of PMNs in the
setting of focal cerebral ischemia/reperfusion. It is
conceivable that LPS priming may exert a preconditioning protective
effect. Whether this LPS effect involves TNF-
or other mechanisms
remains to be elucidated.
| Acknowledgments |
|---|
Received May 6, 1999; revision received October 13, 1999; accepted October 13, 1999.
| References |
|---|
|
|
|---|
2. Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci. 1994;125:310.[Medline] [Order article via Infotrieve]
3.
Kochanek PM, Hallenbeck JM. Polymorphonuclear
leukocytes and monocyte/macrophages in the pathogenesis of
cerebral ischemia and stroke. Stroke. 1992;23:13671379.
4. Hsu CY, Doster K, Hu ZY. Cell-mediated injury. In: Narayan K, Wilberger JE Jr, Povlishock PT, eds. Neurotrauma: A Comprehensive Textbook of Head and Spinal Injury. New York, NY: McGraw Hill, Inc; 1996:14331444.
5. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab. 1999;19:81934.[Medline] [Order article via Infotrieve]
6. Feuerstein GZ, Wang X, Barone FC. Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann N Y Acad Sci. 1997;825:179193.[Medline] [Order article via Infotrieve]
7. Garcia JH, Kamijyo Y. Cerebral infarction: evolution of histopathological changes after occlusion of a middle cerebral artery in primates. J Neuropathol Exp Neurol. 1974;33:408421.[Medline] [Order article via Infotrieve]
8. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol. 1994;144:188199.[Abstract]
9.
Hallenbeck J. Cytokines, macrophages,
and leukocytes in brain ischemia. Neurology. 1997;49:S5S9.
10. Yamasaki Y, Matsuo Y, Zagorski J, Matsuura N, Onodera H, Itoyama Y, Kogure K. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res. 1997;759:103111.[Medline] [Order article via Infotrieve]
11.
Pober JS, Cotran RS. Cytokines and
endothelial cell biology. Physiol Rev. 1990;70:427451.
12.
del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR,
Chang CM. Polymorphonuclear leukocytes occlude capillaries
following middle cerebral artery occlusion and reperfusion in baboons.
Stroke. 1991;22:12761283.
13. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab. 1996;16:11081119.[Medline] [Order article via Infotrieve]
14. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25:869875.[Abstract]
15. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke. 1994;25:14691475.[Abstract]
16. Jiang N, Moyle M, Soule HR, Rote WE, Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol. 1995;38:935942.[Medline] [Order article via Infotrieve]
17. Stroemer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1997;17:597604.[Medline] [Order article via Infotrieve]
18. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, Todd RF III. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol. 1994;35:458463.[Medline] [Order article via Infotrieve]
19.
Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML,
Miyasaka M, Ward PA. Anti-ICAM-1 antibody reduces ischemic cell
damage after transient middle cerebral artery occlusion in the rat.
Neurology. 1994;44:17471751.
20.
Soriano SG, Coxon A, Wang YF, Frosch MP, Lipton SA,
Hickey PR, Mayadas TN. Mice deficient in Mac-1 (CD11b/CD18) are
less susceptible to cerebral ischemia/reperfusion injury.
Stroke. 1999;30:134139.
21.
Pozzilli C, Lenzi GL, Argentino C, Carolei A, Rasura M,
Signore A, Bazzao L, Pozzilli P. Imaging of leukocyte infiltration in
human cerebral infarcts. Stroke. 1985;16:251255.
22.
Akopov SE, Simonian NA, Grigorian GS. Dynamics of
polymorphonuclear leukocyte accumulation in acute cerebral
infarction and their correlation with brain tissue damage.
Stroke. 1996;27:17391743.
23.
Grau AJ, Buggle F, Becher H, Zimmerman E, Speil M, Fent
T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and
viral infection is a risk factor for cerebrovascular ischemia:
clinical and biochemical studies. Neurology. 1998;50:196203.
24. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J. 1988;251:293299.[Medline] [Order article via Infotrieve]
25. Coeffier E, Delautier D, Le Couedic JP, Chignard M, Denizot Y, Benveniste J. Cooperation between platelets and neutrophils for paf-acether (platelet-activating factor) formation. J Leukoc Biol. 1990;47:234243.[Abstract]
26. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP, Nauseef WM. Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Inves. 1998;101:455463.[Medline] [Order article via Infotrieve]
27.
Yip PK, He YY, Hsu CY, Garg N, Marangos P, Hogan EL.
Effect of plasma glucose on infarct size in focal cerebral
ischemia-reperfusion. Neurology. 1991;41:899905.
28.
He YY, Hsu CY, Ezrin AM, Miller MS. Polyethylene
glycol-conjugated superoxide dismutase in focal cerebral
ischemia-reperfusion. Am J Physiol. 1993;265:H252H256.
29.
Bretz U, Baggiolini M. Biochemical and morphological
characterization of azurophil and specific granules of human
neutrophilic polymorphonuclear leukocytes. J Cell
Biol. 1974;63:251269.
30. Xu JA, Hsu CY, Liu TH, Hogan EL, Perot PL Jr, Tai HH. Leukotriene B4 release and polymorphonuclear cell infiltration in spinal cord injury. J Neurochem. 1990;55:907912.[Medline] [Order article via Infotrieve]
31. Picozzi P, Todd NV, Crockard HA. Regional blood-brain barrier permeability changes after restoration of blood flow in postischemic gerbil brains: a quantitative study. J Cereb Blood Flow Metab. 1985;5:1016.[Medline] [Order article via Infotrieve]
32. Qu ZX, Xu J, Perot PL Jr, Hogan EL. A sensitive fluorometric method for measurement of vascular permeability in spinal cord injury. J Neurotrauma. 1991;8:149156.[Medline] [Order article via Infotrieve]
33.
Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of
brain edema on infarct volume in a focal cerebral ischemia
model in rats. Stroke. 1993;24:117121.
34.
Davenpeck KL, Zagorski J, Schleimer RP, Bochner BS.
Lipopolysaccharide-induced leukocyte rolling and adhesion in
the rat mesenteric microcirculation: regulation by glucocorticoids and
role of cytokines. J Immunol. 1998;161:68616870.
35. Schmekel B, Karlsson SE, Linden M, Sundstrom C, Tegner H, Venge P. Myeloperoxidase in human lung lavage, I: a marker of local neutrophil activity. Inflammation. 1990;14:447454.[Medline] [Order article via Infotrieve]
36.
Schroeter M, Jander S, Huitinga I, Witte OW, Stoll G.
Phagocytic response in photochemically induced infarction of rat
cerebral cortex: the role of resident microglia. Stroke. 1997;28:382386.
37.
Bednar MM, Gross CE, Balazy M, Falck JR. Antineutrophil
strategies. Neurology. 1997;49:S20S22.
38. Schurer L, Grogaard B, Gerdin B, Kempski O, Arfors KE. Leukocyte depletion does not affect post-ischemic nerve cell damage in the rat. Acta Neurochir (Wien). 1991;111:5460.[Medline] [Order article via Infotrieve]
39.
Takeshima R, Kirsch JR, Koehler RC, Gomoll AW,
Traystman RJ. Monoclonal leukocyte antibody does not decrease the
injury of transient focal cerebral ischemia in cats.
Stroke. 1992;23:247252.
40. Sherman DG. The Enlimomab acute stroke trial: Final results. Neurol. 1997;48:S33.001 A270. Abstract.[Medline] [Order article via Infotrieve]
41. Hayward NJ, Elliott PJ, Sawyer SD, Bronson RT, Bartus RT. Lack of evidence for neutrophil participation during infarct formation. Exp Neurol. 1996;139:188202.[Medline] [Order article via Infotrieve]
42. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res. 1997;748:267270.[Medline] [Order article via Infotrieve]
43.
Nawshiro H, Tasaki K, Ruetzler CA, Hallenbeck JM.
TNF-
pre-treatment induces protective effects against focal
cerebral ischemia in mice. J Cereb Blood Flow
Metab. 1997;17:483490.[Medline]
[Order article via Infotrieve]
44. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788794.[Medline] [Order article via Infotrieve]
45.
Hallenbeck JM, Dutka AJ, Kochanek PM, Siren A,
Pezeshkpour GH, Feuerstein G. Stroke risk factors prepare rat brainstem
tissues for modified local Shwartzman reaction. Stroke. 1988;19:863869.
46. Dawson DA, Martin D, Hallenbeck JM. Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett. 1996;218:4144.[Medline] [Order article via Infotrieve]
47.
Barone FC, Arvin B, White RF, Miller A, Webb CL,
Willette RN, Lysko PG, Feuerstein GZ. Tumor necrosis factor-alpha: a
mediator of focal ischemic brain injury. Stroke. 1997;28:12331244.
48. Zhao L, Weber PA, Smith JR, Comerford ML, Elliott GT. Role of inducible nitric oxide synthase in pharmacological "preconditioning" with monophosphoryl lipid A. J Mol Cell Cardiol. 1997;29:15671576.[Medline] [Order article via Infotrieve]
49. Kifle Y, Monnier J, Chesrown SE, Raizada MK, Nick HS. Regulation of the manganese superoxide dismutase and inducible nitric oxide synthase gene in rat neuronal and glial cells. J Neurochem. 1996;66:21282135.[Medline] [Order article via Infotrieve]
50.
Meng X, Ao L, Brown JM, Meldrum DR, Sheridan BC, Cain
BS, Banerjee A, Harken AH. LPS induces late cardiac functional
protection against ischemia independent of cardiac and
circulating TNF-alpha. Am J Physiol. 1997;273:H1894H1902.
51. Dawson DA, Furuya K, Gotoh J, Nakao Y, Hallenbeck JM. Cerebrovascular hemodynamics and ischemic tolerance: lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab. 1999;19:616623.[Medline] [Order article via Infotrieve]
Department of Internal Medicine, Cardiovascular Division, University of Iowa College of Medicine, Iowa City, Iowa
| Introduction |
|---|
|
|
|---|
The goal of this study was to further examine the role of leukocytes in brain injury following ischemia using LPS in a rat model of focal ischemia. As part of the protocol, a relatively low dose of LPS was administered 24 hours before ischemia. The results suggest that pretreatment or "preconditioning" with a low dose of LPS 24 hours before ischemia produces increased infiltration of PMNs in the ischemia brain. In contrast to what probably would have been predicted on the basis of previous studies which suggested that infiltration of leukocytes contributes to brain injury after ischemia,1 this increased leukocyte infiltration was associated with neuroprotection (reduced edema and infarct volume). These findings suggest that, at least under some conditions, increased infiltration of PMNs does not contribute to brain injury.
One limitation of the present experiment is that it does not provide insight into the mechanism by which pretreatment with LPS exerts this protective effect in this model. What are some possibilities? There are several levels at which one might hypothesize that LPS preconditioning could exert protective effects for cerebral ischemia, including the reprogramming of gene expression such that subsequent injury in response to ischemia is limited. There is precedent for such reprogramming of gene expression in the heart, where LPS pretreatment produced increased expression of manganese superoxide dismutase and catalase (scavengers of reactive oxygen species).2
Received May 6, 1999; revision received October 13, 1999; accepted October 13, 1999.
| References |
|---|
|
|
|---|
2. Meng X, Brown JM, Rowland RT, Nordeen SK, Banerjee A, Harken AH. Myocardial gene reprogramming associated with a cardiac cross-resistant state induced by LPS preconditioning. Am J Physiol.. 1998;275:C475C483.
This article has been cited by other articles:
![]() |
J. Samanta, T. Alden, K. Gobeske, L. Kan, and J. A. Kessler Noggin Protects Against Ischemic Brain Injury in Rodents Stroke, February 1, 2010; 41(2): 357 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Draisma, M. de Goeij, C. W. Wouters, N. P. Riksen, W. J.G. Oyen, G. A. Rongen, O. C. Boerman, M. van Deuren, J. G. van der Hoeven, and P. Pickkers Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo Innate Immunity, December 1, 2009; 15(6): 360 - 367. [Abstract] [PDF] |
||||
![]() |
R. Meller The Role of the Ubiquitin Proteasome System in Ischemia and Ischemic Tolerance Neuroscientist, June 1, 2009; 15(3): 243 - 260. [Abstract] [PDF] |
||||
![]() |
H.-L. Xu, L. Salter-Cid, M. D. Linnik, E. Y. Wang, C. Paisansathan, and D. A. Pelligrino Vascular Adhesion Protein-1 Plays an Important Role in Postischemic Inflammation and Neuropathology in Diabetic, Estrogen-Treated Ovariectomized Female Rats Subjected to Transient Forebrain Ischemia J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 19 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Rosenzweig, N. S. Lessov, D. C. Henshall, M. Minami, R. P. Simon, and M. P. Stenzel-Poore Endotoxin Preconditioning Prevents Cellular Inflammatory Response During Ischemic Neuroprotection in Mice Stroke, November 1, 2004; 35(11): 2576 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Xu, V. L. Baughman, and D. A. Pelligrino Estrogen Replacement Treatment in Diabetic Ovariectomized Female Rats Potentiates Postischemic Leukocyte Adhesion in Cerebral Venules Stroke, August 1, 2004; 35(8): 1974 - 1978. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Kapinya, D. Lowl, C. Futterer, M. Maurer, K. F. Waschke, N. K. Isaev, and U. Dirnagl Tolerance Against Ischemic Neuronal Injury Can Be Induced by Volatile Anesthetics and Is Inducible NO Synthase Dependent Stroke, July 1, 2002; 33(7): 1889 - 1898. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Kent, V. M. Soukup, and R. H. Fabian Heterogeneity Affecting Outcome From Acute Stroke Therapy: Making Reperfusion Worse Stroke, October 1, 2001; 32(10): 2318 - 2327. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |